CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(MFD) of Magicell-NK in subjects diagnosed with stage I or stage IIa colon cancer post resection from a single site in Taiwan.Durin...
Phase 1
Taoyuan, Taiwan
(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...
Phase 3
Taipei, Taiwan and 250 other locations
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor ...
Phase 1, Phase 2
Taipei, Taiwan and 83 other locations
inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Ph...
Phase 1
Taipei, Taiwan and 63 other locations
in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended do...
Phase 1
Taipei, Taiwan and 12 other locations
to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combinatio...
Phase 1
Taipei, Taiwan and 23 other locations
pembrolizumab or irinotecan that can be given to patients who have cancers with specific molecular alterations called MSIhi (Microsatellite ...
Phase 1
Taipei, Taiwan and 25 other locations
Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET...
Phase 2
Taipei City, Taiwan and 90 other locations
in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The seco...
Phase 1, Phase 2
Taipei, Taiwan and 154 other locations
with standard chemotherapy for the potential treatment of colorectal cancer that:* has spread to other parts of the body (metastatic);* has ...
Phase 3
Taipei, Taiwan and 408 other locations
Clinical trials
Research sites
Resources
Legal